ArticleBMC musculoskeletal disorders2025
Safety of vancomycin-loaded cement spacers for treating gram-positive periprosthetic joint infections in two-stage resection arthroplasty among patients with renal insufficiency.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe standard treatment for periprosthetic joint infections (PJI) typically involves a two-stage resection arthroplasty using antibiotic-loaded bone cement (ALBC) spacers. This study hypothesizes that there is no significant correlation between antibiotic levels in blood and synovial fluid and the patient's kidney function, and that the success rates of staged resection arthroplasty are comparable between groups, specifically targeting gram-positive bacterial infections.
methodsThis retrospective review included patients treated from 2017 to 2022 with two-stage arthroplasty using vancomycin-loaded ALBC spacers, selectively targeting gram-positive infections. Patients with non-gram-positive infections or those with allergies or treatments affecting serum antibiotic levels were excluded. The study assessed comorbidities, renal function, specifics of the spacers, and vancomycin concentrations in joint fluid and blood.
resultsAmong 62 PJI cases analyzed (22 hips and 40 knees), 34 patients (54.8%) had renal insufficiency (RI), associated with significantly lower albumin (2.64 g/dL vs. 3.43 g/dL, p < 0.05) and estimated glomerular filtration rate (eGFR) (58.17 mL/min/1.73 m² vs. 121.74 mL/min/1.73 m², p < 0.05). No significant differences were found in comorbidities, antibiotic regimen, or the weight of the ALBC spacers between the groups (p > 0.05). Both groups exhibited high vancomycin levels in joint fluid, with peak blood vancomycin levels inversely correlated with eGFR (coefficient - 3.612, 95% CI -8.543 to -2.753, p < 0.001). RI patients displayed higher peak blood vancomycin levels (1.23-5.43 mg/L) but remained below toxicity thresholds. The infection-free interval, aseptic revision rates, and bacterial profiles specific to gram-positive species showed no significant differences between the groups.
conclusionSystemic absorption of vancomycin from ALBC spacers was evident in patients with RI and inversely correlated with eGFR, yet remained well below toxic thresholds across all patients. These findings suggest that the use of vancomycin-loaded ALBC spacers appears to be safe for managing gram-positive infections in patients with varying renal function. Additionally, renal insufficiency did not adversely affect the infection-free interval, aseptic revision rates, or bacterial diversity. LEVEL OF EVIDENCE: III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.